Providing access to affordable, good quality HIV/AIDS medicines remains a challenge in Sub-Saharan Africa. Although patent protection is by no means the only barrier to access, it has significant implications for accessibility. Experiences from a number of countries show that local production of HIV/AIDS medicines depends not on research and technology, but also on highly regulated patents and intensive capital investment. These factors pose major challenges to African countries that have ventured into this undertaking. The Agreement on Trade Related Aspects of Intellectual Property Rights...
Providing access to affordable, good quality HIV/AIDS medicines remains a challenge in Sub-Saharan Africa. Although patent protection is by no means t...
